690988-44-4

Upstream product

• 2936-08-5 valproyl chloride 
• 94-09-7 p-aminoethylbenzoate 
• 99-66-1 valproic acid 
• 17022-31-0 ethyl 2-propylpentanoate 
• 23239-88-5 benzocaine hydrochloride 

Downstream Products

• 1610368-79-0 N-(4-(hydrazinecarbonyl)phenyl)-2-propylpentanamide 
• 1638254-75-7 N-(4-(2-benzylidenehydrazinecarbonyl)phenyl)-2-propylpentanamide 
• 1638254-76-8 N-(4-(2-4-chlorobenzylidenehydrazinecarbonyl)phenyl)-2-propylpentanamide 
• 1638254-77-9 N-(4-(2-4-hydroxybenzylidenehydrazinecarbonyl)phenyl)-2-propylpentanamide 
• 1638254-78-0 N-(4-(2-4-nitrobenzylidenehydrazinecarbonyl)phenyl)-2-propylpentanamide 
• 1638254-79-1 N-(4-(2-4-methoxybenzylidenehydrazinecarbonyl)phenyl)-2-propylpentanamide 
• 1638254-80-4 N-(4-(2-(1-phenylethylidene)hydrazinecarbonyl)phenyl)-2-propylpentanamide 
• 1638254-81-5 N-(4-(2-(1-(4-chlorophenyl)ethylidene)hydrazinecarbonyl)phenyl)-2-propylpentanamide 
• 1638254-82-6 N-(4-(2-(1-(4-hydroxyphenyl)ethylidene)hydrazinecarbonyl)phenyl)-2-propylpentanamide 
• 1638254-83-7 N-(4-(2-(1-(4-nitrophenyl)ethylidene)hydrazinecarbonyl)-phenyl)-2-propylpentanamide 

Relevant academic research and scientific papers

Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class i HDAC Enzymes and Cancer Cell Proliferation

AR-42 is an orally active inhibitor of histone deacetylases (HDACs) in clinical trials for multiple myeloma, leukemia, and lymphoma. It has few hydrogen bond donors and acceptors but is a chiral 2-arylbutyrate and potentially prone to racemization. We report achiral AR-42 analogues incorporating a cycloalkyl group linked via a quaternary carbon atom, with up to 40-fold increased potency against human class I HDACs (e.g., JT86, IC50 0.7 nM, HDAC1), 25-fold increased cytotoxicity against five human cancer cell lines, and up to 70-fold less toxicity in normal human cells. JT86 was ninefold more potent than racAR-42 in promoting accumulation of acetylated histone H4 in MM96L melanoma cells. Molecular modeling and structure-activity relationships support binding to HDAC1 with tetrahydropyran acting as a hydrophobic shield from water at the enzyme surface. Such potent inhibitors of class I HDACs may show benefits in diseases (cancers, parasitic infections, inflammatory conditions) where AR-42 is active.

Synthesis and biological activity of Schiff base series of valproyl, N-valproyl glycinyl, and N-valproyl-4-aminobenzoyl hydrazide derivatives

Series of Schiff bases of valproic acid hydrazide, N-valproylglycine hydrazide and N-valproyl-4-aminobenzoyl hydrazide derivatives were synthesized and characterized by IR, NMR (1H- and 13C-NMR) and elemental analysis. The prepared compounds were evaluated in transgenic zebrafish embryos (Tg: flil-1: enhanced green fluorescent protein (EGFP)) for antiangiogenic activity and in HepG2 liver carcinoma cell line for anti cancer activity. The Schiff bases of N-valproylglycine hydrazide derivatives were most potent in term of suppressing angiogenic blood vessels formation and anticancer activity at very low concentration, followed by the Schiff bases of valproic acid hydrazide derivatives which exhibited moderate activity, while the Schiff bases of N-valproyl-4-aminobenzoyl hydrazide derivatives, ethyl 4-(2-propylpentanamido)benzoate (VABE) and N-(4-(hydrazinecarbonyl)phenyl)-2- propylpentanamide (VABH) in contrast exhibited pro-angiogenic activity and weaker anticancer activity which mean that these derivatives targeted a common signaling pathway in term of affecting the blood vessels formation.